by Dr. Joseph Mercola, Mercola:
Story at-a-glance
- Inflammatory bowel diseases remain challenging for medicine, subjecting many to lifelong healthcare expenses and debilitating complications
- DMSO is an “umbrella remedy” treating diverse ailments through reducing inflammation, improving circulation, and reviving dying cells, making it uniquely suited for treating gastrointestinal disorders
- Extensive data shows DMSO produces incredible results for inflammatory bowel disorders (Crohn’s disease, ulcerative colitis, IBS, diverticulitis, leaky gut syndrome, SIBO) and effectively protects gastrointestinal tissues from a wide range of otherwise lethal stressors
TRUTH LIVES on at https://sgtreport.tv/
- Data also supports using DMSO for severe GI tract issues (gastritis, peptic ulcers, liver cirrhosis, cholecystitis, pancreatitis, peritonitis, amyloidosis) and problems like hemorrhoids and prostate enlargement
- This article will review how DMSO can be used to treat those conditions
Living with inflammatory bowel disease (IBD) is a daily balancing act marked by unpredictability. Symptoms like abdominal pain, urgent diarrhea, and fatigue can flare without warning, disrupting plans and demanding constant awareness of diet, stress, and bathroom access. During flares, physical toll — cramping, bloating, sometimes blood in stool — proves exhausting, while remission periods offer relief but never erase underlying uncertainty.
Recently, I discussed the silent epidemic of chronic constipation affecting 15% to 16%1 of adults, with almost all (14% of adults) having constipation with no known cause — resulting in millions placed on lifetime laxatives rather than addressing actual causes. The situation with inflammatory bowel diseases (affecting approximately 1.17% of adults)2 is similar as rates keep increasing, yet no one knows their causes, allowing an increasingly costly status quo to perpetuate.3
This greatly disincentivizes research into actual causes (specific pesticides and herbicides — like glyphosate — have been repeatedly linked to IBD — as have junk food diets and food allergies).4
We’ve seen numerous children develop Crohn’s disease after meningococcal vaccines, but have never seen this link discussed — possibly due to Wakefield’s infamous 1998 paper5 (along with three earlier ones linking the measles vaccine virus to IBD6,7,8) showing children with autism after MMR had significant inflammatory bowel diseases, making this topic taboo.
Note: Vaccines are designed to hyperstimulate the immune system, and extensive evidence links them to autoimmunity (e.g., we’ve seen many develop Crohn’s disease after a college-required meningococcal vaccine, which by design hyperstimulates the immune system).
One of the most common COVID vaccine side effects was exacerbating pre-existing autoimmune disorders (an Israeli government study found 24.2% of booster recipients developed exacerbated autoimmune conditions),9 and we saw numerous debilitating IBD onsets or exacerbations following COVID vaccination. Likewise, in England, after the vaccine rollout, there was a 3-fold increase in disabilities due to both gastrointestinal and autoimmune disorders.10
Finally, as severe illnesses are rarer than mild ones (e.g., far more were disabled than killed by the COVID vaccines),11 a much larger portion of adults are affected by chronic gut inflammation (e.g., 6.1% of Americans have irritable bowel syndrome)12 — with many of these disorders (e.g., leaky gut syndrome or moderate gluten sensitivity) being either understudied or outright dismissed by the medical system.
As such, while reviewing the literature on DMSO, I was immediately struck by the rapid and dramatic IBD improvements reported in many cases. These reports included diagnostic testing confirming complete remission of Crohn’s disease or ulcerative colitis, consistent and rapid relief of the colicky pain commonly associated with IBD, and successful treatment of an intermittent, severe colonic paralysis following colon cancer surgery alongside progressing scleroderma.
Several authors specifically noted that IBD responded exceptionally well to DMSO — something a reader shared they had also observed in their own ulcerative colitis patients. Likewise, I periodically have exchanges like this (which was shared with the reader’s permission):
